Latest oropharyngeal candidiasis Stories

TOKYO, March 12, 2013 /PRNewswire/ -- Sosei Group Corporation (TSE Mothers Index: 4565), the biopharmaceutical company, today announces that its Japanese subsidiary, Sosei Co., Ltd., has initiated a Phase III trial for SO-1105 for the treatment of oropharyngeal candidiasis. The study is an open-label, randomised, multiple centres, parallel-group design (with open active comparator miconazole gel), and will assess efficacy and safety of SO-1105. SO-1105 is an...

TOKYO, July 2, 2012 /PRNewswire/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announces that its wholly owned Japanese subsidiary, Sosei Co., Ltd., has successfully completed a Japanese Phase I trial for SO-1105 for the treatment of oropharyngeal candidiasis. SO-1105 was originally developed by a French pharmaceutical company, BioAlliance Pharma, which received its first marketing authorization for SO-1105 in France in...

TOKYO, March 8, 2012 /PRNewswire/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announces that its wholly owned Japanese subsidiary, Sosei Co., Ltd., has initiated a Japanese Phase I trial for SO-1105 for the treatment of oropharyngeal candidiasis. SO-1105 was originally developed by a French pharmaceutical company, BioAlliance Pharma, which received its first marketing authorization for SO-1105 in France in October 2006....

TOKYO, May 11, 2011 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announces that Sosei Co., Ltd., its wholly owned Japanese subsidiary, acquired development and commercialization rights to Loramyc(R) (miconazole Lauriad(R). Sosei development code: SO-1105) in Japan from BioAlliance Pharma. Loramyc(R) is an antifungal agent, administered as a muco-adhesive buccal tablet for the treatment of oropharyngeal...

WOODCLIFF LAKE, N.J., April 16 /PRNewswire/ -- Strativa Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has approved Oravig (miconazole) buccal tablets for the treatment of oropharyngeal candidiasis (OPC), more commonly known as thrush, in adults and children age 16 and older. Oravig is the first and only local, oral prescription formulation of miconazole - an antifungal medication - approved for this use in the U.S. Oravig, which adheres to the gum,...

BioAlliance Pharma SA (Euronext Paris ISIN code: FR0010095596-BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, has published a turnover of EUR 1,749,000 for the second quarter of 2008, compared with EUR 199,000 recorded for the same period in 2007. The company also presented the initial trends for Loramyc(R) sales in France and its plan for marketing in Europe. BioAlliance Pharma will host two conference calls tomorrow...